Diagnosis and treatment of Wilson's disease experience of 38 years therapy in a spezialised out-patients clinic;Diagnostik und therapie bei Morbus Wilson bericht über 38 jahre behandlung in einer spezialambulanz

Aktuelle Neurologie

Volumn 30, Issue 1, 2003, Pages 18-26

  Kunath, B ^a   Reuner, Ulrike ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COPPER; PENICILLAMINE; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC;

CHROMOSOME 13Q; CLINICAL ARTICLE; COPPER METABOLISM; DRUG TOLERABILITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; LIVER BIOPSY; LIVER FAILURE; LONG TERM CARE; MOLECULAR GENETICS; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTPATIENT; PHENOTYPE; POSITRON EMISSION TOMOGRAPHY; PREGNANCY; PRENATAL DRUG EXPOSURE; REVIEW; SIDE EFFECT; WILSON DISEASE;

EID: 0037293801     PISSN: 03024350     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-37060     Document Type: Review

References (58)

1. Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med 1956; 21: 487-495
2. th Symposium on Wilson's Disease. Delft: University Press, 1991: 79-81
3. Reilly M, Daly L, Hutchinson M. An epidemiological study of Wilson's disease in the Republic of Ireland. J Neurol Psychiat 1993; 56: 298-300
4. Olivarez L, Caggana M, Pass KA et al. Estimate of the frequency of Wilson's disease in the US caucasians population: a mutation analysis approach. Ann Hum Genet 2001; 65: 459-493
5. Schilsky ML. Wilson Disease: Genetic basis of copper toxity and natural history. Semin Liver disease 1996; 16: 83-95
6. Chowrimootoo GFE, Andoh J, Seymour CA. Isolation of coeruloplasmin binding protein in the human liver. Z Gastroenterol 2001; 39: 238
7. Chowrimootoo GFE, Scowcroft H, Seymour CA. Coeruloplasmin isoforms in Wilson's disease in neonates. Arch Dis Child Fetal Neonatal Ed 1998; 79: 198-201
8. Scheinberg IH, Sternlieb I. Wilson's disease and idiopathic copper toxicosis. Am J Clin Nutr 1996; 63: 842-845
9. Betard C, Rasquin-Weber A, Brewer C et al. Localisation of a recessiv gene for North American Indian childhood cirrhosis to chromosome region 16q22-and identification of a shared haplotypre. Am J Hum Genet 2000; 67: 222-228
10. Bull PC, Thomas GR, Rommens JM et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 1993; 5: 327-337
11. Tanzi RE, Petrukhin K, Chernow J et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 1993; 5: 344-350
12. Chu NS, Hung TP. Geographic variations in Wilson's disease. J Neurol Sci 1993; 117: 1-7
13. Caca K, Ferenci P, Kühn H-J et al. High prevalence of the H1069Q mutation in East German patients with Wilson disease: rapid detection of mutations by limited sequencing and phenotype-genotype analysis. J Hepatol 2001; 35: 575-581
14. Sommer G, Genschel J, Czlonkowska A et al. Mutation analysis of the WD gene ATPase7B - Identification of novel mutations. Z Gastroenterol 2001; 39: 244
15. Waldmström E, Portala K, Westermark K. Phenotype and genotype in Swedish patients homozygous formations in Wilson disease gene. Z Gastroenterol 2001; 39: 245
16. Danks DM, Metz G, Sewell R, Prewett EJ. Wilson's disease in adults with cirrhosis but no neurological abnormalities. Brit Med J 1990; 301: 331-332
17. Czlonkowska A, Rodo M. Late onset of Wilson's disease: report of a family. Arch Neurol 1981; 38: 729-730
18. Ross ME, Jacobson JM, Dienstag JE, Martin JB. Late onset Wilson's disease with neurological involvement in the absence of Kayser-Fleischer-rings. Ann Neurol 1985; 17: 411-413
19. Kunath B. Zur Psychopathologie der hepatozerebralen Degeneration. Fortschr Neurol Psychiat 1969; 37: 91-106
20. Menerey KA, Eider W, Brewer GJ et al. The arthropathy of Wilson's disease Clinical and pathological features. J Rheumatol 1988; 15: 331-337
21. Smolarek C, Smolarek E, Stremmel W. Osteoporosis and osteopenia neglected manifestations of wilson disease. Z Gastroenterol 2001; 9: 248
22. Mareckova Z, Marecek Z, Linkart A et al. Cardiac involvement in Wilson's disease. Z Gastroenterol 2001; 39: 247
23. Kuan P. Cardiac Wilson's disease. Chest 1987; 91: 579-583
24. Yoshita K, Furihata K, Taketa S et al. A mutation in the coeruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995; 9: 268-272
25. Biesold D, Kunath B. Hepatocerebrale Degeneration "Morbus Wilson" 1. Mitteilung. Dtsch Gesundheitsw 1969; 24: 1121-1124
26. Günther K, BiesoId D, Lössner J, Löbe J. Zur Diagnostik der Kupferstoff-wechselstörung bei Morbus Wilson. Dtsch Gesundheitsw 1973; 28: 607-611
27. Sternlieb I, Scheinberg IH. The role of radio copper in the diagnosis of Wilson's disease. Gastroenterol 1979; 77: 138-142
28. Starosta-Rubinstein S, Young AB, Kluin K, Hill G et al. Clinical assessment of 31 patients with Wilson's disease. Correlations with structur changes on magnetic resonance imaging. Arch Neurol 1987; 44: 365-370
29. van Wassenaer-van Hall HN, van den Heuvel AG, Jansen GH et al. Cranial MR in Wilson disease: abnormal white matter in extrapyramidal and pyramidal tracts. Am J Neuroradiol 1995; 16: 2021-2027
30. Westermark K, Tedroff J, Thuomas KA et al. Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomographic using dopaminergie markers. Mov Disord 1995; 10: 596-603
31. Cordato DJ, Fulham J, Yiannikas C. Pretreatment and posttreatment positron emission Tomographic Scan Imaging in a 20-year-old Patient with Wilson's disease. Mov Disord 1998; 131: 162-166
32. Kunath B, Reuner U, v Kummer R et al. MRT, FDG-PET and neurophysiology in Wilson disease during therapy. Z Gastroenterol 2001; 39: 243
33. Cumings JN. The effect of BAL in hepatolenticular degeneration. Brain 1951; 74: 10-22
34. Walshe JM. Wilson's disease (hepatolenticular degeneration). In: Vinken PJ, Bruyn GW, Klawans HJ: Handbook of Clinical Neurology, Metabolic and Deficiency Diseases of Nervous System. New York: American Elsevier, 1976; 27, Part 1: 379-414
35. Trautmann B, Storch W. Zum Nachweis von Antikörpern gegen D-Penicillamin. 3 Mitteilung: Nachweis von Antikörpern gegen D-Penicillamin im Serum von Patienten mit Morbus Wilson unter Behandlung mit D-Penicillamin. Pharmazie 1986; 41: 126-127
36. Huang CC, Chû NS. Acute dystonia with thalamic and brainstem lesions after initial penicillamine treatment in wilson's disease. Eur Neurol 1998; 39: 32-37
37. Scheinberg IH, Sternlieb I. Wilson's Disease, Vol 23, Major Problems in Internal Medicine. Philadelphia: Saunders WB, 1984
38. Grasedyck K. D-Penicillamin-Nebenwirkungen, Pathogenese und Risikominderung. Z Rheumatol 1988; 47, Suppl 1: 17-19
39. Dixon HB, Gibbs K, Walshe JM. Preparation of triethylenetetramine dihydrochloride for the treatment of Wilson's disease. Lancet 1972; 1: 853
40. Siegemund R, Lössner J, Günther K et al. Mode of action of triethylentetramin dihydrochloride on copper metabolism in Wilson's disease. Acta Neurol Scand 1991; 83: 364-366
41. Morita J, Yoshino M, Watari H et al. Wilson's disease treatment by triethylenetetramine dihydrochloride (Trientine): long-term observations. Dev Pharmacol Ther 1992; 19: 6-9
42. Scheinberg IH, Jaffe ME, Sternlieb I. The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. New Engl J Med 1987; 317: 209-213
43. Hoogenraad TU, van den Hamer CJ. 3 Years of continuous oral zinc therapy in 4 patients with Wilson's disease. Acta Neurol Scand 1983; 67: 356-364
44. Hoogenraad TU. Wilson's Disease. London: Saunders WB Company Ltd, 1996
45. Brewer GJ, Dick RD, Johnson VD et al. Treatment of Wilson's disease with zinc. XV Long-term follow up studies. J Lab Clin Med 1998; 132: 264-278
46. Najda J, Stella-Holowiecka B, Machalski M. Low-dose zinc administration as an effective Wilson disease treatment. Biol Trace Elem Res 2001; 80: 281-284
47. Anderson LA, Hakojarvi SL, Boudreaux SK. Zinc acetat treatment in Wilson's disease. Ann Pharmacother 1998; 32: 78-87
48. Walshe JM. Orphan drugs: food for thought. In: Scheinberg IH, Walshe JM (eds): Orphan Diseases and Orphan Drugs. Manchester: University Press, 1986: 1-5
49. Brewer GJ, Dick RD, Johnson V et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 1994; 51: 545-554
50. Brewer GJ, Dick RD, Johnson V et al. Treatment of Wilson's disease with ammonium tetrathiomolybdate. II. Initial therapy in 33 neurologically affected patients and follow up with zinc therapy. Arch Neurol 1996; 53: 1017-1025
51. Brewer GJ. Tetrathiomolybdate for initial therapy of neurological Wilson disease. Z Gastroenterol 2001; 39: 251
52. Messner U, Gunter HH, Niesert S. Morbus Wilson und Schwangerschaft. Literaturübersicht und kasuistische Mitteilung. Z Geburtshilfe Neonatal 1998; 202: 77-79
53. Brewer GJ, Johnson VD, Dick RD et al. Treatment of Wilson's disease with zinc. VXVII: treatment during pregnancy. Hepatology 2000; 31: 364-370
54. Carpenter TO, Carnes DL, Anast CS. Hypoparathyroidism in Wilson's disease. New Engl J Med 1983; 309: 873-877
55. Czlonkovska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with D-Penicillamin and zinc sulfate. J Neurol 1996; 243: 269-273
56. Walshe JM. Penicillamine: the treatment of first choise for patients with Wilson's disease. Mov Disord 1999; 14: 545-550
57. Brewer GJ. Penicillamin should not be used as initial therapy in Wilson's disease. Mov Disord 1989; 14: 551-554
58. Le Witt PA. Penicillamine as a controversial treatment for Wilson's disease. Mov Disord 1999; 14: 553-556